Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action (Q35932017)

11 August 2017

1 reference

title

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action (English)

1 reference

11 August 2017

2

Hagop Kantarjian

1 reference

11 August 2017

3

Jorge Cortes

1 reference

11 August 2017

1

Elias Jabbour

1 reference

11 August 2017

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

45

1 reference

11 August 2017

11

1 reference

11 August 2017

2187-2195

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

11 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Enzymatic modification of proteins with a geranylgeranyl isoprenoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

The prenylation of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

RAS and leukemia: from basic mechanisms to gene-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Ras regulatory interactions: novel targets for anti-cancer intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Multiple ras effector pathways contribute to G(1) cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

The challenge of acute myeloid leukemia in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190412331272677

10.1080/10428190412331272677

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15512806